Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - uniQure N.V. | a17-22633_1ex32d1.htm |
EX-31.2 - EX-31.2 - uniQure N.V. | a17-22633_1ex31d2.htm |
EX-31.1 - EX-31.1 - uniQure N.V. | a17-22633_1ex31d1.htm |
EX-10.1 - EX-10.1 - uniQure N.V. | a17-22633_1ex10d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2017
OR
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-36294
uniQure N.V.
(Exact name of Registrant as specified in its charter)
The Netherlands |
|
Not applicable |
Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands
(Address of principal executive offices) (Zip Code)
+31-20-240-6000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of large accelerated filer accelerated filer and smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
|
Accelerated filer x |
Non accelerated filer (do not check if smaller reporting company) |
|
Smaller reporting company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act Yes o No x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes o No x
As of August 3, 2017, the registrant had 25,629,099 shares of common shares, par value 0.05, outstanding.
EXPLANATORY NOTE
This Amendment No. 1 to the Form 10-Q (this Amendment) amends the Quarterly Report on Form 10-Q of uniQure N.V. for the period ending June 30, 2017 filed on August 8, 2017 (the Form 10-Q) for the sole purpose of refiling Exhibit 10.1 (certain portions of which are omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission (the SEC)) and in connection therewith, to amend Part II, Item 6 of the 10-Q and the Exhibit Index to the 10-Q. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment.
No other changes have been made to the Form 10-Q. This Amendment does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way the disclosures made in the original Form 10-Q.
EXHIBIT INDEX
3.1 |
|
|
|
10.1* |
Letter Agreement dated July 27, 2017 between uniQure biopharma B.V. and Chiesi Farmaceutici S.p.A. |
|
|
10.2 |
|
|
|
10.3 |
|
|
|
10.4 |
|
|
|
31.1* |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer |
|
|
31.2* |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer |
|
|
32.1 |
|
|
|
101 |
The following financial information from our Quarterly Report on Form 10-Q for the period ended June 30, 2017, filed with the Securities and Exchange Commission on August 8, 2017 is formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Comprehensive Loss; (iii) Consolidated Statements of Shareholders Equity; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements (tagged as blocks of text) (incorporated by reference to Exhibit 101 of the Companys quarterly report on Form 10-Q for the quarter ended June 30, 2017 (file no. 0001-36294) filed with the Securities and Exchange Commission). |
Confidential treatment has been requested for certain information contained in this Exhibit (indicated by double asterisks). Such information has been omitted and filed separately with the SEC
* Filed herewith.
Furnished herewith.
Item 6. Exhibits
See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
UNIQURE, N.V. | |
|
| |
|
|
|
|
By: |
/s/ Matthew Kapusta |
|
Matthew Kapusta | |
|
Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) |